[Innovations in the treatment of gastroduodenal ulcers].
It has long been known that gastroduodenal ulcers may heal spontaneously; this is the placebo effect in which the healing rate ranges from 20% at 2 weeks to 80% at 8 weeks. Two or three weeks can be gained by using cimetidine or ranitidine, with healing rates of 42% at 2 weeks and 85% at 6 weeks. Ranitidine probably has less side-effects than cimetidine. A new drug, omeprozole, appears to be much more potent but is not yet available. A vagolytic drug with specific affinity to the stomach (pirenzepine), as well as low-dosage bismuth bi-citrate and gastric mucosa protectors (sucralfate) are now returning in force.
D000535:Aluminum / Q000627:therapeutic use; D000863:Antacids / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D001570:Benzodiazepinones / Q000627:therapeutic use; D001729:Bismuth / Q000627:therapeutic use; D002927:Cimetidine / Q000627:therapeutic use; D005663:Furans / Q000627:therapeutic use; D006801:Humans; D009942:Organometallic Compounds; D010437:Peptic Ulcer / Q000188:drug therapy*; D010890:Pirenzepine; D010919:Placebos; D011453:Prostaglandins / Q000627:therapeutic use; D011899:Ranitidine; D013392:Sucralfate
D000863:Antacids; D000897:Anti-Ulcer Agents; D001570:Benzodiazepinones; D005663:Furans; D009942:Organometallic Compounds; D010919:Placebos; D011453:Prostaglandins; D010890:Pirenzepine; D013392:Sucralfate; D002927:Cimetidine; D011899:Ranitidine; D000535:Aluminum; C002791:bismuth tripotassium dicitrate; D001729:Bismuth
Du nouveau dans le traitement des ulcères gastro-duodénaux.